- Janjigian, Y., Al-Batran, S., Wainberg, Z., Muro, K., Molena, D., Van Cutsem, E.,…Tabernero, J. (2025). Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC). Journal of Clinical Oncology, 43(17_Suppl), LBA5-LBA5. https://doi.org/10.1200/JCO.2025.43.17_suppl.LBA5 (Meeting abstract)
Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC)
on 6 d'octubre de 2025
with No hi ha comentaris
Deixa un comentari